2,745 Shares in NuVasive, Inc. (NUVA) Acquired by Tiedemann Wealth Management LLC

Tiedemann Wealth Management LLC bought a new position in shares of NuVasive, Inc. (NASDAQ:NUVA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,745 shares of the medical device company’s stock, valued at approximately $205,000.

A number of other hedge funds have also made changes to their positions in NUVA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of NuVasive by 0.4% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,454 shares of the medical device company’s stock worth $502,000 after buying an additional 27 shares during the period. US Bancorp DE boosted its stake in shares of NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock worth $180,000 after buying an additional 41 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of NuVasive by 0.5% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 8,720 shares of the medical device company’s stock worth $651,000 after buying an additional 43 shares during the period. World Asset Management Inc boosted its stake in shares of NuVasive by 2.3% in the first quarter. World Asset Management Inc now owns 3,117 shares of the medical device company’s stock worth $233,000 after buying an additional 69 shares during the period. Finally, Keybank National Association OH boosted its stake in shares of NuVasive by 0.7% in the first quarter. Keybank National Association OH now owns 12,667 shares of the medical device company’s stock worth $946,000 after buying an additional 86 shares during the period.

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive, Inc. (NASDAQ:NUVA) traded down 1.14% during trading on Thursday, reaching $70.44. 719,507 shares of the company traded hands. The company has a market capitalization of $3.57 billion, a P/E ratio of 73.91 and a beta of 0.86. The firm has a 50-day moving average price of $73.11 and a 200-day moving average price of $69.98. NuVasive, Inc. has a 52 week low of $53.05 and a 52 week high of $77.88.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings results on Tuesday, April 25th. The medical device company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.37 by $0.01. The company had revenue of $249.86 million during the quarter, compared to analyst estimates of $250.52 million. NuVasive had a net margin of 3.29% and a return on equity of 12.26%. The firm’s revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.34 EPS. Analysts forecast that NuVasive, Inc. will post $2.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “2,745 Shares in NuVasive, Inc. (NUVA) Acquired by Tiedemann Wealth Management LLC” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://sportsperspectives.com/2017/05/18/2745-shares-in-nuvasive-inc-nuva-acquired-by-tiedemann-wealth-management-llc.html.

NUVA has been the subject of a number of analyst reports. Canaccord Genuity set a $69.00 price objective on shares of NuVasive and gave the stock a “buy” rating in a research note on Monday, January 23rd. Jefferies Group LLC reissued a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of NuVasive in a research note on Thursday, February 16th. BMO Capital Markets reissued a “buy” rating and issued a $82.00 price objective on shares of NuVasive in a research note on Tuesday, April 11th. Barclays PLC reissued an “overweight” rating and issued a $80.00 price objective (up from $76.00) on shares of NuVasive in a research note on Thursday, February 16th. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $76.00 price objective on shares of NuVasive in a research note on Monday. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $75.50.

In related news, insider Jason Hannon sold 24,840 shares of the business’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $74.22, for a total value of $1,843,624.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is currently owned by insiders.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

5 Day Chart for NASDAQ:NUVA

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply